Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 1, 2016, Pages 156-164.e3

  Gerber, Lynn ^a   Estep, Michael ^a,b   Stepanova, Maria ^b   Escheik, Carey ^b   Weinstein, Ali ^a   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Fatigue; HCV; IL10; PDGF; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEDIPASVIR PLUS SOFOSBUVIR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RIBAVIRIN; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; CYTOKINE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ANEMIA; ANXIETY DISORDER; ARTICLE; CENTRAL FATIGUE; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); CLINICALLY OVERT FATIGUE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; FATIGUE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT OF CANCER THERAPY FATIGUE SCORING SYSTEM; FUNCTIONAL STATUS ASSESSMENT; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MENTAL DISEASE; MUSCLE FATIGUE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEROTONIN BLOOD LEVEL; SHORT FORM 36; SKIN DISEASE; VIRAL CLEARANCE; ADULT; AGED; BLOOD; BLOOD ANALYSIS; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84958964633     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.07.035     Document Type: Article

References (30)

1. Poynard T., Cacoub P., Ratziu V., et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002, 9:295-303.
2. Marcellin F., Préau M., Ravaux I., et al. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007, 8:320-327.
3. Sarkar S., Jiang Z., Evon D.M., et al. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 2012, 57:946-952.
4. Dwight M.M., Kowdley K.V., Russo J.E., et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000, 49:311-317.
5. Glacken M., Coates V., Kernohan G., et al. The experience of fatigue for people living with hepatitis C. J Clin Nurs 2003, 12:244-252.
6. Swain M. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol 2006, 20:181-188.
7. Kallman J., O'Neil M.M., Larive B., et al. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007, 52:2531-2539.
8. Fitts R.H. The muscular system: fatigue processes. ACSM's advanced exercise physiology 2006, 178-196. Lippincott Williams & Wilkins, Philadelphia, PA. C.M. Tipton (Ed.).
9. Jason L.A., Evans M., Brown M., et al. What is fatigue? pathological and nonpathological fatigue. PM&R 2010, 2:327-331.
10. Enoka R.M., Stuart D.G. Neurobiology of muscle fatigue. J Appl Physiol 1992, 72:1631-1648.
11. Gandevia S.C., Allen G.M., McKenzie D.K. Central fatigue: critical issues, quantification and practical implications. Adv Exp Med Biol 1995, 384:281-294.
12. Leavitt V.M., DeLuca J. Central fatigue: issues related to cognition, mood and behavior, and psychiatric diagnoses. PM&R 2010, 2:332-337.
13. Kraus M.R., Schäfer A., Teuber G., et al. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology 2013, 58:497-504.
14. Scott J., Gilles L., Fu M., et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 an. J Viral Hepat 2015, 22:639-650.
15. Spiegel B.M.R., Younossi Z.M., Hays R.D., et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41:790-800.
16. Younossi Z.M., Guyatt G., Kiwi M., et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45:295-300.
17. Krupp L.B., LaRocca N.G., Muir-Nash J., et al. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123.
18. Yellen S.B., Cella D.F., Webster K., et al. Measuring fatigue and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. J Pain Symptom Manage 1997, 13:63-74.
19. Afdahl N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
20. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II-psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263.
21. Younossi Z.M., Stepanova M., Marcellin P., et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 2015, 61:1798-1808.
22. Weinstein A.A., Baghi H., Escheik C., et al. Two types of fatigue in subjects with chronic liver disease can be distinguished through correlations with physical activity and mental symptoms. Hepatology 2014, 60:93A.
23. Hwang S.S., Chang V.T., Cogswell J., et al. Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center. Cancer 2002, 94:2481-2489.
24. Testoni B., Durantel D., Lebossé F., et al. Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut 2015.
25. Savic D., Stojiljkovic M., Lavrnja I., et al. Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacol Immunotoxicol 2014, 36:433-441.
26. Gu L., Tsey S., Horner R.M., et al. Control of Th2 polarization by chemokine monocyte chemoattractant protein-1. Nature 2000, 404:407-411.
27. Shahrbanian S., Duquette P., Kuspinar A., et al. Contribution of symptom clusters to multiple sclerosis consequences. Qual Life Res 2015, 24:617-629.
28. Hilsabeck R.C., Anstead G.M., Webb A.L., et al. Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C. J Neuroimmunol 2010, 221:53-61.
29. Perry W., Hilsabeck R.C., Hassanein T.I. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 2008, 53:307-321.
30. Felger J.C., Cole S.W., Pace T.W.W., et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychol Med 2012, 42:1591-1603.